Juniper Pharmaceuticals (NASDAQ: JNP) is one of 114 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Juniper Pharmaceuticals to related businesses based on the strength of its dividends, institutional ownership, profitability, earnings, risk, valuation and analyst recommendations.

Profitability

This table compares Juniper Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Juniper Pharmaceuticals 13.94% 21.49% 14.40%
Juniper Pharmaceuticals Competitors -2,920.14% -57.23% -9.08%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Juniper Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Juniper Pharmaceuticals 0 1 2 0 2.67
Juniper Pharmaceuticals Competitors 806 3579 6175 156 2.53

Juniper Pharmaceuticals presently has a consensus price target of $23.00, suggesting a potential upside of 374.23%. As a group, “Pharmaceuticals” companies have a potential upside of 22.08%. Given Juniper Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Juniper Pharmaceuticals is more favorable than its competitors.

Insider and Institutional Ownership

36.2% of Juniper Pharmaceuticals shares are held by institutional investors. Comparatively, 43.0% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.6% of Juniper Pharmaceuticals shares are held by company insiders. Comparatively, 12.0% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Juniper Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Juniper Pharmaceuticals $57.69 million $9.49 million 6.55
Juniper Pharmaceuticals Competitors $8.11 billion $2.65 billion 0.29

Juniper Pharmaceuticals’ competitors have higher revenue and earnings than Juniper Pharmaceuticals. Juniper Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Juniper Pharmaceuticals has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Juniper Pharmaceuticals’ competitors have a beta of 0.88, indicating that their average share price is 12% less volatile than the S&P 500.

Summary

Juniper Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.

Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.